Staff Directory

Filter By Surname
Filter By Position
Filter By Keyword
Filter By Cancer Type
Search
Professor Daniel M Berney
Honorary Professor of Genito-urinary Pathology; Consultant Pathologist

My focus is on the pathology and natural history of prostate, testicular and penile cancer working to translate basic research into practical treatments for patients with novel tests and bespoke predictive treatments.

Dr Gunnel Halldén
Reader in Cancer Gene Therapy

The research in our team is focused on the development of novel treatment strategies to target prostate and pancreatic cancers using genetically modified viruses that target, replicate and kill cancer cells but leave normal cells unharmed.

Professor Yong-Jie Lu
Professor of Molecular Oncology

We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.

Professor Thomas Powles
Professor of Genitourinary Oncology, Director, Barts Cancer Centre, Lead for Solid Tumour Research

My main research interests are in genital and urinary cancers, leading a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.

Dr Prabhakar Rajan
Clinical Senior Lecturer in Urology

My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, and liquid biopsy-derived molecular biomarkers of treatment outcomes.

Dr Chinedu A. Anene
Bioinformatician

I am a bioinformatician and am currently developing a computer vision pipeline to quantify and characterise tumour hypoxia in squamous cell carcinomas.

Dr John Foster

My project focuses on understanding how the proteins involved in RNA binding and alternative splicing of pre-mRNA are regulated.

Dr Helen Ross-Adams

The aim of my work is to develop clinically-relevant biomarkers that could aid in earlier disease detection, predict treatment response, and inform clinical management of patients.